RegeneRx Biopharmaceuticals, Inc. RGRX
Set alert
At close · Oct 30
- YTD
- +266.67%
- 1 year
- +450.00%
- Open
- 0.161
- Prev close
- 0.0011
- Mkt cap
- 1.65K
- Vol
- 252
- Avg vol
- 47
- EPS
- -0.71
- P/E
- 0.00
More statistics
- Low
- 0.161
- High
- 0.161
- Earnings
- Jan 2, 2023
News
3 years ago prnewswire.com
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection,…
3 years ago prnewswire.com
RegeneRx Receives Stockholder Approval for Reverse Stock Split
ROCKVILLE, Md. , Aug. 7, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection,…
3 years ago prnewswire.com
RegeneRx To Extend Consent Solicitation Vote
ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair,…
5 years ago prnewswire.com
Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis
ROCKVILLE, Md., Oct. 6, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and…
5 years ago prnewswire.com
RegeneRx Issues Letter To Stockholders
ROCKVILLE, Md., July 22, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection,…
5 years ago prnewswire.com
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome
ROCKVILLE, Md., July 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and…
5 years ago prnewswire.com
RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement
ROCKVILLE, Md., July 1, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and…
5 years ago prnewswire.com
RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement
ROCKVILLE, Md., June 28, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and…
5 years ago prnewswire.com
RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome
ROCKVILLE, Md., May 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and…
5 years ago prnewswire.com
RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial
ROCKVILLE, Md., March 18, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection,…
5 years ago prnewswire.com
RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial
ROCKVILLE, Md., Feb. 24, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection,…
5 years ago prnewswire.com
RegeneRx Comments on ARISE-3 Clinical Trial
ROCKVILLE, Md., Jan. 26, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection,…